The Jails Were Finally Learning to Treat Opioid Withdrawal. Then Medetomidine Showed Up.

The nurse at the county jail had seen opioid withdrawal before. She knew the sweating, the cramping, the clock-watching, the way people beg and then stop begging and then go very quiet. What she had not seen — what nothing in her training had prepared her for — was a patient two days into withdrawal whose blood pressure kept crashing. Not spiking, the way it does in opioid withdrawal. Crashing. Sedated and trembling at the same time.

STAT News reported on June 26 that medetomidine — a powerful alpha-2 adrenergic agonist used primarily as a large-animal veterinary sedative — is appearing in the illicit opioid supply, and that its presence is creating withdrawal presentations that standard jail protocols are not built to handle.

The drug supply changed faster than the protocols. That’s how people die in custody.

The same pattern played out with xylazine starting in 2021. The same thing is beginning now with medetomidine. And if you work in a jail health unit, an OTP, or a county emergency department anywhere in Arizona, the question is not whether this is coming. It’s already here. The question is what you do about it tonight.

What Medetomidine Is — and Why It’s Different From Everything Else in the Supply

Here is the plain-language version before the pharmacology: medetomidine makes you very calm, very sedated, and significantly slows your heart rate and drops your blood pressure. It’s used in horses and large dogs. It is not approved for use in humans. It is extremely potent — about 10 times more potent than xylazine, its chemical cousin. And critically, naloxone does not reverse it.

Medetomidine belongs to a class of drugs called alpha-2 adrenergic receptor agonists. Think of the brain’s fight-or-flight system as a dial — norepinephrine (adrenaline’s chemical sibling) turns the dial up, toward alertness, elevated heart rate, vigilance. Alpha-2 agonists turn it down, hard. They hit receptors that tell your brainstem to slow everything down: breathing rate, heart rate, blood pressure, arousal. The opioid receptors naloxone blocks are a completely different system. Giving someone medetomidine-overdose naloxone is like pressing the wrong button on the wrong circuit board. Nothing happens.

This is why the CDC’s xylazine guidance — which applies with equal or greater force to medetomidine — is so unnerving for first responders: “Patients taking opioids plus xylazine may require more intensive treatment for successful outcomes.” The CDC wrote that about a drug that’s 1/10th the potency of what’s now showing up. With medetomidine, the treatment complexity is worse.

How It Got Into the Supply — and Why Jails See It First

Adulterants follow the economics of the drug supply. Fentanyl displaced heroin because it was cheaper per unit of effect and could be cut into almost anything. Xylazine showed up in the fentanyl supply partly because it extends the sedative effect and partly because it’s freely available at veterinary suppliers without meaningful controls. Medetomidine follows the same economic logic — it’s potent, it’s unscheduled as a veterinary compound in most of the supply chain, and it extends the high at minimal cost per kilogram.

What makes jails a uniquely dangerous site for this to surface: people arrive with unknown contamination profiles, go through intake with inadequate toxicology (most jails do not run comprehensive drug screens, and standard panels don’t include medetomidine), and are then managed on withdrawal protocols designed for uncomplicated opioid dependence. The medications used in those protocols — clonidine, loperamide, hydroxyzine — were designed for a world in which opioid withdrawal is the primary clinical challenge. Medetomidine’s cardiovascular suppression creates a physiological picture that looks like opioid withdrawal complicated by something else, and without a name for the something else, the clinical team guesses wrong.

If you have ever been in a withdrawal unit — and if you’re reading this from the inside of that experience, not the outside — you already know that the standard of care is low before you add any of this. You know the way staff count the minutes to shift change. You know what it means to be seen versus not seen when you are at your most physically vulnerable.

You know what it means to be seen versus not seen when you are at your most physically vulnerable.

The medetomidine problem lands on top of a system that was already failing the people in it.

The Withdrawal No One Was Trained For

Opioid withdrawal, in the absence of complicating adulterants, follows a recognizable trajectory: 12–24 hours after last use, anxiety and restlessness. Then nausea, muscle aches, sweating, dilated pupils, elevated blood pressure and heart rate. Peak discomfort around 48–72 hours. Gradual resolution by days 5–7. It is agonizing. It is rarely lethal in otherwise healthy adults. It is also something jail medical staff have learned, over the past decade, to recognize and manage with MOUD protocols — particularly buprenorphine induction, which SAMHSA’s decommissioning of the DATA waiver system as of June 1, 2026 now allows any licensed prescriber to initiate.

Medetomidine disrupts this picture in two directions simultaneously. The alpha-2 agonist component suppresses the cardiovascular elevation that’s characteristic of opioid withdrawal — masking a key clinical sign, making patients appear less severely withdrawn than they are. Then, as the medetomidine also metabolizes out (its half-life is roughly 3–5 hours in humans, based on extrapolation from veterinary data), the uncovered opioid withdrawal surges back, sometimes severely. The cardiovascular instability during this unmasking phase — the crash — is where the danger concentrates.

In a jail medical unit where there is one nurse covering 200 people and vital signs are checked once per shift, a patient going through this unmasking is going to be checked on at exactly the wrong frequency. The vitals will look fine at 6 AM. They will not be fine at 9 AM. The check happens at noon.

The Arizona Picture

This story matters everywhere. It matters particularly in Arizona.

Arizona’s AHCCCS spent $582.3 million on substance use disorder treatment services in State Fiscal Year 2025 — an enormous investment, and a meaningful one. Maricopa County has been expanding medication-assisted treatment access in county jails as part of its opioid settlement fund allocations, connecting people initiated on MOUD during incarceration with community treatment upon release. This is exactly right. This is what the evidence says to do. The Administration for Children and Families recently expanded the 50% federal Medicaid match for OUD medications to cover parents at risk of their children entering foster care — another mechanism that could bring more people into treatment at the point of contact with the legal system.

None of these investments account for medetomidine. None of the protocols for jail-based MOUD induction include guidance for managing withdrawal when an alpha-2 agonist of unknown potency is also present. That’s not a critique of the people who built the programs. They built them for the drug supply as it existed when the evidence base was assembled. The supply has changed again.

Arizona’s settlement-funded jail MOUD expansion is a system worth protecting. Medetomidine arriving without updated clinical guidance is the fastest way to produce catastrophic outcomes that set the whole enterprise back — politically, and in the families who lose someone during withdrawal in a facility that was supposedly providing treatment.

A Pattern We’ve Watched Before

We have been here before. In 2021, toxicology labs in Philadelphia, Baltimore, and Providence started returning results they didn’t recognize: xylazine, a veterinary tranquilizer, in samples pulled from people who had overdosed. Nobody at the state health department had a protocol. Nobody at the county jail had a protocol. The overdose response community spent roughly 18 months playing catch-up — running education, rewriting MOUD induction guidance, distributing wound care supplies for xylazine’s distinctive skin necrosis, arguing about whether test strips would help or harm. In that 18 months, the CDC estimates xylazine spread to every major drug market in the country.

The medetomidine clock started earlier than people think. The overall decline in overdose deaths — down 13.2% to 69,147 for the 12 months ending January 2026 — is real progress. It is not a reason to look away from what’s moving through the supply right now. Progress in one year’s number does not insulate anyone from next year’s contamination. We learned that lesson with xylazine. The medetomidine pattern is close enough to the xylazine pattern that there is no excuse for treating it as novel.

The overall decline in overdose deaths — down 13.2% to 69,147 for the 12 months ending January 2026 — is real progress.

What Providers Need to Do This Week

If you run clinical services in a jail, prison, or detention facility:

Screen for medetomidine by name when ordering intake toxicology. Standard CLIA panels don’t detect it — you need to request it specifically or use point-of-care immunoassay strips where they exist. If your lab doesn’t run it, ask them to add it. If they can’t, contact your state health department’s overdose surveillance program and ask what’s in the supply in your county right now.

Revise your withdrawal monitoring protocol to include cardiovascular suppression as a sign to investigate, not dismiss. A patient whose blood pressure is low during what should be opioid withdrawal is not stable. They are presenting with a drug you may not have identified.

Consult with the regional poison control center — the American Association of Poison Control Centers can be reached at 1-800-222-1222, and they are tracking medetomidine presentations in real time.

Call your AHCCCS regional contact and your SOR IV program officer and ask what’s been reported in your county. Arizona’s $34.8 million SOR IV award exists precisely to create this kind of surveillance infrastructure. Use it.

The Kicker

The people most likely to encounter medetomidine withdrawal complications in the next six months are incarcerated. They are in facilities with minimal medical oversight. They have no advocate, no family member who will notice they are deteriorating, no discharge planner whose job it is to make sure they get through withdrawal intact. The criminal legal system has a documented, decades-long record of failing people in medical distress during incarceration — not because jail staff are uniquely cruel, but because the system is not built for the level of medical complexity it is now being handed.

Medetomidine is not going to stop because there is no protocol for it. The protocol has to get built fast — faster than the 18 months it took to respond to xylazine — or the jail-based MOUD programs that Arizona and other states are rightly investing in are going to be recording deaths in the same facilities where they just opened treatment intake.

A person in withdrawal in a county jail is at their most physically vulnerable at exactly the moment when the institution around them has the fewest resources to respond. The answer to that is not a different paragraph about why this is hard. The answer is a protocol, today, for the drug that is already in the supply.